StockData

Immutep vs NewAmsterdam Pharma

IMMP and NAMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMMP and NAMS compare

Immutep grew revenue faster over the last twelve months (134% versus −88.9% for NewAmsterdam Pharma).

Immutep keeps more of each dollar of sales as profit, with a net margin of −328% compared with −3644% at NewAmsterdam Pharma.

Immutep scores higher on the StockData Score (8 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMMPNAMS
Size and price
Share price$3.26$19.39
Change, 1 year−91.2%−49.4%
Change, 5 years−95.2%98.1%
Beta (5Y)4.321.57
Employees46100
StockData Score
Total score8 (better)6
Valuation score00
Growth score2 (better)0
Performance score11
Health score55
Dividend score00
Growth
Revenue growth (TTM)134% (better)−88.9%
Revenue growth, 5Y average43.5%–
Profitability
Operating margin–−3432%
Net margin−328% (better)−3644%
FCF margin−230% (better)−2018%
Return on equity−77.3%−36.8% (better)
Return on invested capital–−1046%
Financial health
Debt / equity0.000.00
Current ratio5.699.03 (better)
Piotroski F-score23 (better)
Ownership
Held by insiders0.89%22.0%
Insider net buying, 12 months–−$63.0M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.